EGFR-IN-69

EGFR-IN-69 (compound 17g) is a potent EGFR inhibitor, with IC50 values of 4.3, 6.6 and 25.6 nM against EGFRL858R/T790M/C797S, EGFRL858R/T790M, and EGFR19del/T790M/C797S, respectively. EGFR-IN-69 can be used for non-small-cell-lung-cancer (NSCLC) research[1].

Product Specifications

CAS Number

[2433837-65-9]

UNSPSC

12352005

Target

EGFR

Type

Reference compound

Related Pathways

JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/egfr-in-69.html

Purity

99.58

Solubility

DMSO : 12.5 mg/mL (ultrasonic; warming; heat to 80°C)

Smiles

O=S(N1C=C(C2=NC(NC3=CC(Cl)=C(N4CCC(N5CCN(C)CC5)CC4)C=C3OC)=NC=C2Cl)C6=C1C=CC=C6)(CC)=O

Molecular Formula

C31H37Cl2N7O3S

Molecular Weight

658.64

References & Citations

[1]Chen H, et al. Conformational Constrained 4- (1-Sulfonyl-3-indol) yl-2-phenylaminopyrimidine Derivatives as New Fourth-Generation Epidermal Growth Factor Receptor Inhibitors Targeting T790M/C797S Mutations. J Med Chem. 2022 May 12;65 (9) :6840-6858.